18-Jun-2026
TipRanks (Thu, 18-Jun 8:40 AM ET)
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
PRNewswire (Thu, 18-Jun 8:00 AM ET)
Globe Newswire (Sun, 14-Jun 6:05 PM ET)
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Globe Newswire (Thu, 14-May 4:05 PM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Wed, 13-May 6:00 AM ET)
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Tue, 21-Apr 5:30 PM ET)
Globe Newswire (Fri, 17-Apr 3:00 PM ET)
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Globe Newswire (Thu, 16-Apr 6:00 AM ET)
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Globe Newswire (Thu, 9-Apr 6:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of June 18, 2026, ZYME stock price was flat at $23.14 with 677,401 million shares trading.
ZYME has a beta of 0.10, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.00 to the broad based SPY ETF.
ZYME has a market cap of $1.70 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $2 million in Revenue and -$.59 earnings per share. This fell short of revenue expectation by $-35 million and missed earnings estimates by -$.49.
In the last 3 years, ZYME traded as high as $29.75 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a return of +83.2%, while the SPY ETF gained +26.9%. However, in the most recent history, ZYME shares have underperformed the stock market with its stock returning -1.3% in the last 3 month period and -7.8% for the last 2 week period, while SPY has returned +13.5% and -1.1%, respectively.
ZYME support price is $22.54 and resistance is $23.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.